Sandoz Group AGSDZXF 18 ROC (Joel Greenblatt) % is 55.88% as of Dec. 2025, which is 56% above its 10-year median of 35.78. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 977 Drug Manufacturers companies, Sandoz Group AG ranks better than 85.98% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sandoz Group AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 55.88%.
The historical rank and industry rank for Sandoz Group AG's ROC (Joel Greenblatt) % or its related term are showing as below:
SDZXF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.83 Med: 35.78 Max: 62.55
Current: 53.33
During the past 4 years, Sandoz Group AG's highest ROC (Joel Greenblatt) % was 62.55%. The lowest was 10.83%. And the median was 35.78%.
SDZXF's ROC (Joel Greenblatt) % is ranked better than 85.98% of 977
companies
in the Drug Manufacturers industry
Industry Median: 11.37
vs SDZXF: 53.33
Sandoz Group AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Sandoz Group AG (OTCPK:SDZXF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sandoz Group AG ROC (Joel Greenblatt) % Related Terms
Sandoz Group AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SDZXF vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's ROC (Joel Greenblatt) % falls into.
Sandoz Group AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 55.88% mean?
Sandoz Group AG (SDZXF) has a ROC (Joel Greenblatt) % of 55.88% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sandoz Group AG and its competitors. This is 56% above median its historical median of 35.78. Over the past decade, Sandoz Group AG's ROC (Joel Greenblatt) % has ranged from 10.83 to 62.55. According to the industry distribution chart, Sandoz Group AG ranks #137 out of 977 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Sandoz Group AG's ROC (Joel Greenblatt) % too high?
Sandoz Group AG's current ROC (Joel Greenblatt) % of 55.88% is 56% above median its 10-year median of 35.78. Over the past 10 years, this metric has ranged from a low of 10.83 to a high of 62.55. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.37. Sandoz Group AG's value of 55.88% is 391.5% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #137 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #137 out of 977 companies for ROC (Joel Greenblatt) %. This places Sandoz Group AG in the top 14% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.37. Sandoz Group AG's value of 55.88% is 391.5% above this benchmark. Historically, Sandoz Group AG's own ROC (Joel Greenblatt) % has ranged from 10.83 to 62.55 over the past decade. While the company's 10-year median is 35.78 vs. the industry median of 11.37, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.37, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current ROC (Joel Greenblatt) % of 55.88% is 391.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current ROC (Joel Greenblatt) % is 55.88%, which is 56% above median its own 10-year median of 35.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current ROC (Joel Greenblatt) % of 55.88%. The current ROC (Joel Greenblatt) % is 55.88%, which is 56% above median its 10-year median of 35.78 and 391.5% above the Drug Manufacturers industry median of 11.37. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current ROC (Joel Greenblatt) % is 55.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score
Get the complete analysis for SDZXF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 